dm+d
Unassigned
New Medicines
Gastroparesis in diabetes, and gastrointestinal functional disorders
Information
New molecular entity
AbbVie
AbbVie
Development and Regulatory status
Discontinued
Discontinued
Discontinued
Sep 20Abbvie terminates all trials and discontinues development of relamorelin in constipation, diabetic gastroparesis and gastrointestinal disorders, due to undisclosed business reasons [6].
Category
Ghrelin agonist derived from the natural hormone
A substantial proportion of diabetic patients experience symptoms of gastroparesis - vomiting nausea, abdominal pain and bloating [1].
Gastroparesis in diabetes, and gastrointestinal functional disorders
Subcutaneous